Addition of Bevacizumab to Standard Radiation Therapy and Daily Temozolomide Is Associated With Minimal Toxicity in Newly Diagnosed Glioblastoma Multiforme

Article ID	Journal	Published Year	Pages	File Type
8227819	International Journal of Radiation OncologyBiologyPhysics	2012	9 Pages	PDF

Abstract

The addition of bevacizumab to standard radiation therapy and daily temozolomide was found to be associated with minimal toxicity in patients newly diagnosed with GBM.

Keywords

bevacizumab Temozolomide Radiation therapy Glioblastoma multiforme

Related Topics

Physical Sciences and Engineering Physics and Astronomy Radiation

Preview

Addition of Bevacizumab to Standard Radiation Therapy and Daily Temozolomide Is Associated With Minimal Toxicity in Newly Diagnosed Glioblastoma Multiforme

Authors

James J. M.D., Annick M.D., FRCPC, John P. M.D., David A. M.D., Katherine B. M.D., Ph.D., James E. Ph.D., Jennifer M.S., Leighann B.S., Stevie B.A., John M.D., Ph.D., Allan M.D., Henry S. M.D.,